Redox activation of metal-based prodrugs as a strategy for drug delivery
Name
graf and lippard ADDR.pdf
Size
2.39 MB
Format
Adobe PDF
Checksum (MD5)
020e6da5a0e808f7414f24e54d6565c8
Author(s)
Graf, Nora
Lippard, Stephen J.
Date Issued
January 2012
Journal
Advanced Drug Delivery Reviews
Citation
Graf, Nora, and Stephen J. Lippard. “Redox Activation of Metal-Based Prodrugs as a Strategy for Drug Delivery.” Advanced Drug Delivery Reviews 64, no. 11 (August 2012): 993-1004.
Version
Author's final manuscript
Abstract
This review provides an overview of metal-based anticancer drugs and drug candidates. In particular, we focus on metal complexes that can be activated in the reducing environment of cancer cells, thus serving as prodrugs. There are many reports of Pt and Ru complexes as redox-activatable drug candidates, but other d-block elements with variable oxidation states have a similar potential to serve as prodrugs in this manner. In this context are compounds based on Fe, Co, or Cu chemistry, which are also covered. A trend in the field of medicinal inorganic chemistry has been toward molecularly targeted, metal-based drugs obtained by functionalizing complexes with biologically active ligands. Another recent activity is the use of nanomaterials for drug delivery, exploiting passive targeting of tumors with nano-sized constructs made from Au, Fe, carbon, or organic polymers. Although complexes of all of the above mentioned metals will be described, this review focuses primarily on Pt compounds, including constructs containing nanomaterials.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.addr.2012.01.007
